文献速递心外重症与机械循环支持

年轻患者当代耐久性左心室辅助装置支持的长期结局:EUROMACS分析

Long-term outcomes of contemporary durable left ventricular assist device support in younger patients: a European registry for patients with mechanical circulatory support (EUROMACS) analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2026-10-07

基于EUROMACS注册数据,分析2850例接受HeartMate 3植入的成年患者,按年龄分层比较5年设备支持生存率。年轻患者(<50岁)5年设备支持生存率74.7%,高于年长组,且因心肌恢复而移除LVAD的比例更高;无出血生存率亦更优,但无卒中、无设备相关感染和无设备故障生存率各组相似。

要点

  • 年轻患者(<50岁)5年设备支持生存率74.7%,年长组逐渐降低。
  • 年轻患者因心肌恢复移除LVAD比例4.3%,高于其他年龄组。
  • 无出血生存率年轻组更优,但无卒中、感染、故障生存率各组相似。

核心结论

  • 当代欧洲实践中,<50岁患者LVAD植入后5年生存率高达74.7%,接近心脏移植等待队列水平。
  • 结果支持进一步研究在移植前延长LVAD支持,以最大化特定年轻候选者的终身获益。

研究设计与样本

  • 基于EUROMACS注册的回顾性分析,纳入2850例接受HeartMate 3植入的成年患者。
  • 按年龄分层:<50岁占23.5%,50-59岁占29.7%,60-69岁占38.0%,≥70岁占8.8%。

主要发现

  • 5年设备支持生存率:<50岁74.7%,50-59岁65.5%,60-69岁53.9%,≥70岁48.8%(p < 0.001)。
  • 因心肌恢复移除LVAD比例:<50岁4.3%,50-59岁1.8%,60-69岁2.3%,≥70岁0.4%(p = 0.031)。
  • 5年累积死亡发生率:<50岁20.8%,50-59岁29.1%,60-69岁40.8%,≥70岁49.5%(p < 0.001),受较高心脏移植率驱动。
  • 无出血生存率年轻患者显著更高(p < 0.001);无卒中、无设备相关感染、无设备故障生存率各组相似。

临床怎么用

  • 年轻患者LVAD植入后长期生存良好,可考虑将延长LVAD支持作为移植前策略进行进一步研究。
  • 年龄分层有助于医患沟通预后,但需注意年轻患者无卒中、感染、故障生存率与年长组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Superior survival outcomes have been reported for younger patients receiving durable left ventricular assist devices (LVADs) in INTERMACS. We explored whether these findings extend to contemporary European practice leveraging on EUROMACS (European Registry for Patients with Mechanical Circulatory Support). METHODS: Adult patients undergoing implantation of current-generation magnetically levitated LVADs in EUROMACS were stratified according to age groups. The primary outcome was 5-year on-device survival, censoring at heart transplantation (HT) or LVAD explantation. Secondary outcomes included LVAD explant for myocardial recovery, and survival free from major adverse events (bleeding, stroke, device-related infection, or device malfunction). Death incidence accounting for HT and support cessation as competing risks was also calculated. RESULTS: A total of 2,850 patients undergoing HeartMate 3 implantation were included (<50 years: 23.5%; 50-59 years: 29.7%; 60-69 years: 38.0%; ≥70 years: 8.8%). Younger patients had fewer comorbidities, a higher prevalence of non-ischemic cardiomyopathy, and INTERMACS profile ≤3.Younger patients had superior on-device 5-yr survival (<50 years: 74.7%; 50-59 years: 65.5%; 60-69 years: 53.9%; ≥70 years: 48.8%; p < 0.001) and LVAD explantation for myocardial recovery (<50 years: 4.3%; 50-59 years: 1.8%; 60-69 years: 2.3%; ≥70 years: 0.4%; p = 0.031). Accounting for competing outcomes, the 5-year cumulative incidence of death was lowest among younger patients (<50 years: 20.8%; 50-59 years: 29.1%; 60-69 years: 40.8%; ≥70 years: 49.5%; p < 0.001), driven by higher HT rates. Survival free from bleeding was significantly higher in younger patients (p < 0.001). In contrast, 5-year freedom from stroke, device-related infection, and device malfunction was similar across age groups. CONCLUSIONS: In contemporary European practice, patients <50 yrs undergoing LVAD implant had high 5-yr survival approaching that reported in cohorts of patients listed for HT. These findings support further investigation of prolonged LVAD support before HT as a potential strategy to maximize lifetime benefit in selected motivated younger candidates.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gallone G, Veen KM, Bernhardt AM, et al. Long-term outcomes of contemporary durable left ventricular assist device support in younger patients: a European registry for patients with mechanical circulatory support (EUROMACS) analysis. Eur J Cardiothorac Surg. 2026. PMID: 42842428. doi:10.1093/ejcts/ezag234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。